tetano
Editor, Senior Moderator
PLoS One
. 2021 Jul 29;16(7):e0255263.
doi: 10.1371/journal.pone.0255263. eCollection 2021.
Long-term effects of coronavirus disease 2019 on the cardiovascular system, CV COVID registry: A structured summary of a study protocol
Victor Arévalos[SUP] 1 [/SUP], Luis Ortega-Paz[SUP] 1 [/SUP], Diego Fernandez-Rodríguez[SUP] 2 [/SUP], Víctor Alfonso Jiménez-Díaz[SUP] 3 [/SUP], Jordi Bañeras Rius[SUP] 4 [/SUP], Gianluca Campo[SUP] 5 [/SUP], Miguel Rodríguez-Santamarta[SUP] 6 [/SUP], Armando Pérez de Prado[SUP] 6 [/SUP], Antonio Gómez-Menchero[SUP] 7 [/SUP], José Francisco Díaz Fernández[SUP] 7 [/SUP], Claudia Scardino[SUP] 8 [/SUP], Nieves Gonzalo[SUP] 9 [/SUP], Alberto Pernigotti[SUP] 10 [/SUP], Fernando Alfonso[SUP] 11 [/SUP], Ignacio Jesús Amat-Santos[SUP] 12 [/SUP], Antonio Silvestro[SUP] 13 [/SUP], Alfonso Ielasi[SUP] 14 [/SUP], José María de la Torre[SUP] 15 [/SUP], Gabriela Bastidas[SUP] 16 [/SUP], Josep Gómez-Lara[SUP] 17 [/SUP], Manel Sabaté[SUP] 1 [/SUP], Salvatore Brugaletta[SUP] 1 [/SUP], CV COVID-19 Registry Investigators
Affiliations
Abstract
Background: Patients presenting with the coronavirus-2019 disease (COVID-19) may have a high risk of cardiovascular adverse events, including death from cardiovascular causes. The long-term cardiovascular outcomes of these patients are entirely unknown. We aim to perform a registry of patients who have undergone a diagnostic nasopharyngeal swab for SARS-CoV-2 and to determine their long-term cardiovascular outcomes.
Study and design: This is a multicenter, observational, retrospective registry to be conducted at 17 centers in Spain and Italy (ClinicalTrials.gov number: NCT04359927). Consecutive patients older than 18 years, who underwent a real-time reverse transcriptase-polymerase chain reaction (RT-PCR) for SARS-CoV2 in the participating institutions, will be included since March 2020, to August 2020. Patients will be classified into two groups, according to the results of the RT-PCR: COVID-19 positive or negative. The primary outcome will be cardiovascular mortality at 1 year. The secondary outcomes will be acute myocardial infarction, stroke, heart failure hospitalization, pulmonary embolism, and serious cardiac arrhythmias, at 1 year. Outcomes will be compared between the two groups. Events will be adjudicated by an independent clinical event committee.
Conclusion: The results of this registry will contribute to a better understanding of the long-term cardiovascular implications of the COVID19.
. 2021 Jul 29;16(7):e0255263.
doi: 10.1371/journal.pone.0255263. eCollection 2021.
Long-term effects of coronavirus disease 2019 on the cardiovascular system, CV COVID registry: A structured summary of a study protocol
Victor Arévalos[SUP] 1 [/SUP], Luis Ortega-Paz[SUP] 1 [/SUP], Diego Fernandez-Rodríguez[SUP] 2 [/SUP], Víctor Alfonso Jiménez-Díaz[SUP] 3 [/SUP], Jordi Bañeras Rius[SUP] 4 [/SUP], Gianluca Campo[SUP] 5 [/SUP], Miguel Rodríguez-Santamarta[SUP] 6 [/SUP], Armando Pérez de Prado[SUP] 6 [/SUP], Antonio Gómez-Menchero[SUP] 7 [/SUP], José Francisco Díaz Fernández[SUP] 7 [/SUP], Claudia Scardino[SUP] 8 [/SUP], Nieves Gonzalo[SUP] 9 [/SUP], Alberto Pernigotti[SUP] 10 [/SUP], Fernando Alfonso[SUP] 11 [/SUP], Ignacio Jesús Amat-Santos[SUP] 12 [/SUP], Antonio Silvestro[SUP] 13 [/SUP], Alfonso Ielasi[SUP] 14 [/SUP], José María de la Torre[SUP] 15 [/SUP], Gabriela Bastidas[SUP] 16 [/SUP], Josep Gómez-Lara[SUP] 17 [/SUP], Manel Sabaté[SUP] 1 [/SUP], Salvatore Brugaletta[SUP] 1 [/SUP], CV COVID-19 Registry Investigators
Affiliations
- PMID: 34324524
- DOI: 10.1371/journal.pone.0255263
Abstract
Background: Patients presenting with the coronavirus-2019 disease (COVID-19) may have a high risk of cardiovascular adverse events, including death from cardiovascular causes. The long-term cardiovascular outcomes of these patients are entirely unknown. We aim to perform a registry of patients who have undergone a diagnostic nasopharyngeal swab for SARS-CoV-2 and to determine their long-term cardiovascular outcomes.
Study and design: This is a multicenter, observational, retrospective registry to be conducted at 17 centers in Spain and Italy (ClinicalTrials.gov number: NCT04359927). Consecutive patients older than 18 years, who underwent a real-time reverse transcriptase-polymerase chain reaction (RT-PCR) for SARS-CoV2 in the participating institutions, will be included since March 2020, to August 2020. Patients will be classified into two groups, according to the results of the RT-PCR: COVID-19 positive or negative. The primary outcome will be cardiovascular mortality at 1 year. The secondary outcomes will be acute myocardial infarction, stroke, heart failure hospitalization, pulmonary embolism, and serious cardiac arrhythmias, at 1 year. Outcomes will be compared between the two groups. Events will be adjudicated by an independent clinical event committee.
Conclusion: The results of this registry will contribute to a better understanding of the long-term cardiovascular implications of the COVID19.